Results 171 to 180 of about 104,177 (305)
ABSTRACT Conventional treatments for oral candidiasis often fail due to the complexities of the oral environment and the increasing antifungal drug resistance. Therefore, there is a growing demand for new therapies that optimize drug bioavailability, allowing for lower therapeutic doses while enhancing cytocompatibility, maintaining antifungal, anti ...
Carolina Yoshi Campos Sugio +6 more
wiley +1 more source
Frailty and Oral Health: Associations with Candidiasis, Prosthesis Use, and Hyposalivation. [PDF]
Centanaro-Vera R +5 more
europepmc +1 more source
Human inborn errors of immunity underlying superficial or invasive candidiasis
A. Puel
semanticscholar +1 more source
ABSTRACT Mycobacterium avium subspecies paratuberculosis (MAP) as the infectious cause of Crohn's disease and the use of antimycobacterial (anti‐MAP) therapies in its treatment remain topics of controversy. A major limitation accepting this view is that irrefutable evidence that MAP causes Crohn's disease—the demonstration that long‐term remission ...
Paul Pavli, Peter R. Gibson
wiley +1 more source
Signs and symptoms of oral candidiasis associated with health factors and resistant <i>Candida</i> infections in a Northern Ontario patient cohort. [PDF]
Czajka KM +9 more
europepmc +1 more source
Comparative evaluation of the Candida agglutinin test, precipitin test, and germ tube dispersion test in the diagnosis of candidiasis [PDF]
Donna L. Oblack +2 more
openalex +1 more source
A series of azomethine‐pyrazole derivatives bearing a para‐substituted azo‐phenyl ring is straightforwardly prepared. The new compounds display an elevated antifungal activity against various Candida species and Cryptococcus neoformans strains. DFT and molecular docking calculations are used to determine possible routes of action through interactions ...
María Isabel Murillo +8 more
wiley +1 more source
Efficacy of botanical antifungal and conventional antifungal in the treatment of oral candidiasis: a systematic review and meta-analysis. [PDF]
Nurdiana +4 more
europepmc +1 more source

